glp1gradedGLP-1 provider ratings

Grade notice. No grade is published anywhere on this site: the weights are provisional and are not signed off, so no letter grade, weighted total or ranking appears on any page.

Compounded or branded: what a GLP-1 price says

A compounded semaglutide preparation and an FDA-approved semaglutide product are not the same thing, and the difference is most of the reason one figure can be a fraction of another. Across 3018 published figures on 408 sellers’ own pages, 1868 do not say which is being sold. Split those figures by how they name the drug and the silence turns out to be almost perfectly selective.

Ellis Brandt built this site’s grading methodology and maintains it. Last re-read September 2026.

How often the class is stated at all

Every figure was read with the words around it. Where the seller stated, beside the number, that the product is compounded or that it is the branded drug, that is recorded; where the page said neither, that is recorded too, as a value rather than as a gap.

Whether the class is stated, across 3018 published figures

  1. The page says compounded

    746 of 3018

  2. The page says branded

    400 of 3018

  3. The page says neither

    1868 of 3018 — Counted as what the seller published, not as a missing value.

Read from each seller’s own public pages, September 2026. Every figure classified by reading the seller’s own words around it; see how we grade.

1150 of 3018 figures — 38 per cent — carry a statement of the class. A further 4 name both classes at once with nothing in the page saying which the figure belongs to, and are counted separately for that reason. A reader looking at any single price on any single site has better than even odds of not being told what kind of drug the money buys.

Where it is stated, and where it is not

The interesting number is not how often the class is stated. It is when. Split the same 3018 figures by how each one names the drug and the disclosure rate moves from near-total to near-absent across four groups that sum to 3018.

How often the class is stated, by how the figure names the drug

Percentage of the figures in each group that state the class. Group sizes differ and are printed on each row; the four groups sum to 3018 figures.

  1. Names a brand-name drug

    319 of 320

    A brand name settles it. Those six are FDA-approved finished products, so a figure that names one has already said what is being sold.

  2. Names a molecule only

    736 of 1853

    A molecule name settles nothing. Semaglutide is the ingredient in an FDA-approved product and in a compounded preparation alike, so the name alone does not say which the money buys.

  3. Says a GLP-1, not which

    84 of 432

    A figure that says only “GLP-1” names neither the product nor the ingredient, so nothing about it can be compared with anything.

  4. Prices something else

    11 of 413

    A figure priced against a different product tells a reader nothing about the GLP-1 on the same site, and this site counts it separately for that reason.

Read from each seller’s own public pages, September 2026.

Where the figure names a brand-name drug, the class is stated on 319 of 320 figures. Where it names a molecule — semaglutide, tirzepatide — it is stated on 736 of 1853. Those two groups are the two halves of the question, and they are the wrong way round.

A brand name answers the question by itself: Wegovy and Zepbound are FDA-approved finished products, so a page that names one has already said what it is selling before it says anything else. A molecule name answers nothing. Semaglutide is the ingredient in an approved product and in a pharmacy-compounded preparation alike, and it is precisely there — on 1853 figures, the largest group of the four — that 1117 pages leave it unsaid.

Two readings of that fit the same numbers. One is that a seller says “compounded” when it has to and stays quiet when it can. The other is simply that a page naming a brand has more room to be specific about everything. This site counts what was published and does not claim to know which; the count is the finding, and it holds either way.

The same question, asked once per seller

Everything above counts figures. This section counts sellers, over 408 — the sellers that published at least one figure tied to a GLP-1, which is neither the 588 whose pages were opened nor the 60 this site prints a price for.

What 408 sellers state across every figure they publish

Share of the 408 sellers publishing at least one figure tied to a GLP-1. The last three rows overlap; the first does not overlap any of them.

  1. Never state the class on any figure

    167 of 408

    Not one published figure on the site says whether the drug is compounded or the branded product.

  2. State compounded on at least one

    166 of 408

  3. State branded on at least one

    113 of 408

  4. State both, on different figures

    39 of 408

    These sellers sell both kinds. On their pages the class is not a house style; it is a property of the individual offer, which is what makes its absence elsewhere legible.

Read from each seller’s own public pages, September 2026.

167 of 408 sellers never state the class on any figure they publish. At the other end, 39 state both across different figures — they sell a compounded preparation and a branded product, and their own pages distinguish them. That group matters more than its size: it proves the distinction is one these businesses can make on a price page when they choose to.

413 of the 3018 figures price something that is not a GLP-1 at all and are counted here with everything else, because the question — did the page say what kind of product this price buys — is the same question. What drug a GLP-1 price is for counts that group on its own.

How this differs from the roster count

This site already publishes a compounded-or-branded count, and it is a different number over a different set. What sellers do not publish reports 34 of the 60 sellers whose figure states what it buys — one figure per seller, on the sellers whose figure states what dose it buys, which is the only set this site prints prices from.

This page reports 1868 of 3018 figures across 408 sellers. Neither number is a version of the other and neither corrects the other. One asks what the sellers on this site’s boards disclosed; this one asks what the published GLP-1 web says. They are stated separately, with their own denominators attached, because an absence claim carried over to a set it was never read on is the exact failure this site was built to report in other people’s pages.

Every per-seller finding lives on that seller’s own page with its read date beside it, under every seller we have read. What is counted, and what each measurement is worth, is on how we grade. No letter grade, score or ranking is published on this site: the weights behind them are provisional and are not signed off.

The other findings

Each is counted over its own set, and the sets are different sizes on purpose. The denominator is printed beside every one.

Where the comparable sellers are compared

One board per buying decision. Whether the page said compounded or branded is a column on every one of them, and “the page does not say” is selectable as its own filter across the sellers this site prices.